2015-002135-17: Clinical efficay, pharmacokinetics and pharmacodynamics, and intra-subject variability of insulin Glargine U-300 vs Glargine U-100 in type 1 diabetes. Efficacia clinica, farmacocinetica, farmacodinamica e variabilit¿ intra-soggetto dell¿analogo dell¿insulina ad azione ritardo Glargine U300 vs Glargine U100 nel Diabete Mellito Tipo 1 |
|
|
| Ongoing | 3 | 62 | Europe | insulina glargine, na, Concentrate for solution for injection, Toujeo, LANTUS - 100 U/ML SOLUZIONE INIETTABILE - USO SOTTOCUTANEO - CARTUCCIA(VETRO) IN PENNA PRE-RIEMPITA (SOLOSTAR)3 ML 6 PENNE PRERIEMPITE | UNIVERSITà DEGLI STUDI DI PERUGIA, Fondi di ricerca e collaborazioni farmaceutiche | Type 1 Diabetes Mellitus Diabete Mellito tipo 1, Type 1 Diabetes Mellitus Diabete Mellito tipo 1, Diseases [C] - Hormonal diseases [C19] | | | | |
| Active, not recruiting | 3 | 319 | US | Afrezza, Technosphere Insulin, Rapid-acting Insulin Analog, insulin aspart, insulin lispro, insulin glulisine, Novolog®, Fiasp®, Humalog®, Admelog®, Apidra®, Basal Insulin, insulin glargine, insulin degludec, insulin detemir, Lantus®, Abasaglar®, Basaglar®, Semglee®, Toujeo®, Tresiba®, Levemir® | Mannkind Corporation, Jaeb Center for Health Research | Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2 | 09/24 | 04/25 | | |
